08/09/22 8:00 AMNasdaq : AGEN earningsAgenus Provides Corporate Update and Second Quarter 2022 Financial ReportBotensilimab (Fc-enhanced CTLA-4)/balstilimab (PD-1) combination data presented at the 2022 ESMO World GI Congress demonstrated remarkable clinical activity in microsatellite stable colorectal cancer (MSS CRC) Agenus expects to present additional botensilimab expansion cohort data at upcomingRHEA-AIneutral
08/02/22 8:30 AMNasdaq : AGEN conferencesAgenus to Participate at BTIG Biotechnology ConferenceAgenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will attend the BTIG Biotechnology Conference. AgenusRHEA-AIneutral
08/01/22 8:30 AMNasdaq : AGEN clinical trialAgenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid TumorsAgenus Inc. (Nasdaq: AGEN), an immuno-oncology companyRHEA-AIneutral
07/27/22 8:30 AMNasdaq : AGEN earningsAgenus to Provide Corporate Update and Second Quarter 2022 Financial ReportAgenus (NASDAQ: AGEN) an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced it willRHEA-AIneutral
06/30/22 8:30 AMNasdaq : AGEN conferencesAgenus to Participate at William Blair’s Biotech Focus ConferenceAgenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that Dr. Steven O’Day, Chief Medical Officer, will participate in aRHEA-AIneutral
06/29/22 7:00 AMNasdaq : AGEN Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI CongressOverall response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients with a median of 4 prior lines of therapy Responses to botensilimab/balstilimab were durable, with 80% ongoing at data cut-off and median duration of response not reached Global, randomized Phase 2 studyRHEA-AIpositive
06/21/22 8:30 AMNasdaq : AGEN conferencesAgenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI CongressAgenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will host a hybrid webcast to discussRHEA-AIneutral
06/10/22 8:00 AMNasdaq : AGEN GSK’s RSV vaccine candidate for older adults, containing Agenus’ QS-21 STIMULON™ as part of GSK’s AS01 adjuvant, reports positive pivotal data supporting initiation of global regulatory submissionsFirst RSV vaccine candidate to show statistically significant and clinically meaningful efficacy in adults aged 60 years and above Third AS01 adjuvanted vaccine containing QS-21 STIMULON to deliver meaningful clinical benefit against infections in a registrational program Global regulatoryRHEA-AIneutral
05/31/22 8:30 AMNasdaq : AGEN Agenus Advances Portfolio with 6 Clinical CollaborationsAgenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that it has entered into 3 new clinical collaborations withRHEA-AIvery positive
05/25/22 8:30 AMNasdaq : AGEN Agenus Announces Virtual Annual Shareholders MeetingAgenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that its Annual Shareholders Meeting will begin at 3:30 p.m. ET onRHEA-AIneutral